Standard BioTools Inc.
LAB
$1.06
-$0.0143-1.34%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -26.48% | 41.08% | -42.17% | -62.61% | 5.82% |
| Total Depreciation and Amortization | -37.93% | 44.72% | 105.85% | -45.26% | -59.25% |
| Total Amortization of Deferred Charges | -- | -360.73% | -117.83% | -- | -- |
| Total Other Non-Cash Items | 36.36% | -13.70% | 152.53% | -397.49% | -10.24% |
| Change in Net Operating Assets | 174.98% | -165.57% | 82.11% | -776.77% | -453.93% |
| Cash from Operations | 49.55% | 28.63% | 37.50% | -344.32% | -23.21% |
| Capital Expenditure | -49.98% | -16.42% | -148.02% | -901.28% | 91.38% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -100.00% | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 206.51% | -154.85% | 34.44% | 397.75% | 73.40% |
| Cash from Investing | 183.30% | -161.45% | -84.20% | 2,524.91% | 73.73% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 100.00% | -555.36% | -50.06% |
| Issuance of Common Stock | 672.06% | -95.16% | 1,851.39% | -82.90% | 426.25% |
| Repurchase of Common Stock | 35.71% | 99.76% | -168.94% | -6,260.92% | 57.66% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | -- | -- |
| Cash from Financing | -2,725,900.00% | 99.99% | -43.72% | -1,867.40% | 13.83% |
| Foreign Exchange rate Adjustments | 34.56% | -358.43% | -323.81% | -109.13% | 256.46% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 27.12% | -243.09% | -107.31% | 943.78% | 55.38% |
